Antibodies are under development to treat a variety of cancers, such as lymphomas, colon, and breast cancer. A major limitation to greater efficacy for this class of drugs is poor distribution in vivo. Localization of antibodies occurs slowly, often in insufficient therapeutic amounts, and distributes heterogeneously throughout the tumor. While the microdistribution around individual vessels is important for many therapies, the total amount of antibody localized in the tumor is paramount for many applications such as imaging, determining the therapeutic index with antibody drug conjugates, and dosing in radioimmunotherapy. With imaging and pretargeted therapeutic strategies, the time course of uptake is critical in determining when to take ...
A nonlinear compartmental model has been developed to optimise tumour targeting using radiolabelled ...
With the decreasing cost of monoclonal antibody production, radioimmunotherapy (RIT) has rapidly eme...
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, February 2013...
Antibodies are under development to treat a variety of cancers, such as lymphomas, colon, and breast...
Targeting tumors with antibody-based therapeutics is a complex task presenting multiple kinetic barr...
The use of antibody-based therapeutics has proven very promising for clinical applications in cancer...
The use of antibody-based therapeutics has proven very promising for clinical applications in cancer...
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2008.Vita.Inc...
Immune checkpoint blockades prescribed in the neoadjuvant setting are now under active investigation...
With the decreasing cost of monoclonal antibody production, radioimmunotherapy (RIT) has rapidly eme...
Inverse correlations of tumor uptake (u), measured in percent injected dose per gram, with tumor mas...
AbstractDirect injection of therapies into tumors has emerged as an administration route capable of ...
<div><p>The ability to use a systemically injected agent to image tumor is influenced by tumor chara...
The major problem of tumour radioimmunotherapy remains the low tumour antibody uptake and this leads...
Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapie...
A nonlinear compartmental model has been developed to optimise tumour targeting using radiolabelled ...
With the decreasing cost of monoclonal antibody production, radioimmunotherapy (RIT) has rapidly eme...
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, February 2013...
Antibodies are under development to treat a variety of cancers, such as lymphomas, colon, and breast...
Targeting tumors with antibody-based therapeutics is a complex task presenting multiple kinetic barr...
The use of antibody-based therapeutics has proven very promising for clinical applications in cancer...
The use of antibody-based therapeutics has proven very promising for clinical applications in cancer...
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2008.Vita.Inc...
Immune checkpoint blockades prescribed in the neoadjuvant setting are now under active investigation...
With the decreasing cost of monoclonal antibody production, radioimmunotherapy (RIT) has rapidly eme...
Inverse correlations of tumor uptake (u), measured in percent injected dose per gram, with tumor mas...
AbstractDirect injection of therapies into tumors has emerged as an administration route capable of ...
<div><p>The ability to use a systemically injected agent to image tumor is influenced by tumor chara...
The major problem of tumour radioimmunotherapy remains the low tumour antibody uptake and this leads...
Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapie...
A nonlinear compartmental model has been developed to optimise tumour targeting using radiolabelled ...
With the decreasing cost of monoclonal antibody production, radioimmunotherapy (RIT) has rapidly eme...
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, February 2013...